AUG 12, 2015 11:28 AM PDT

Overstimulating Cancer Cells

Researchers at Baylor College of Medicine have developed a drug candidate that overstimulates proteins critical to tumor growth. In the August 10 issue of Cancer Cell, as reported in Science Daily, the researchers demonstrate that the drug candidate inhibits tumor growth in a mouse model of breast cancer and efficiently kills a broad range of human cancer cells. They claim that rapid cell division strains cancer cells, and "the approach works by tipping cell stress over the edge" (http://www.sciencedaily.com/releases/2015/08/150810132114.htm).
Cancer cells were treated with a control (left) and the overstimulating compound MCB-613 (right).
According to co-senior study author David Lonard of Baylor College of Medicine, "No prior drug has been previously developed or proposed that actually stimulates an oncogene to promote therapy. Our prototype drug works in multiple types of cancers and encourages us that this could be a more general addition to the cancer drug arsenal."

Cancer cells acquire mutations in oncogenes, which can transform cells into cancer cells. Research on identifying oncogenes that could be targeted by cancer drugs has uncovered the role of members of the steroid receptor coactivator (SRC) family of oncogenes. They appear to have great potential as therapeutic targets, because they are "at the nexus of key signaling pathways that cancer cells use to quickly grow, spread to other tissues, and acquire drug resistance," the researchers explain. In a prior investigation, Lonard and co-senior study author Bert O'Malley of Baylor College of Medicine screened compounds to discover "SRC-inhibiting molecules that kill a wide variety of cancer cells and inhibit tumor growth in animal models."

According to an article in the International Journal of Biological Sciences (Walsh CA, Qin L, Tien JCY, Young LS, Xu J. The Function of Steroid Receptor Coactivator-1 in Normal Tissues and Cancer. Int J Biol Sci 2012; 8(4):470-485. doi:10.7150/ijbs.4125), "Coregulator proteins were initially thought to be mere ‘acceptor proteins' that facilitated the interaction of specific ligand-bound nuclear receptors with general transcriptional machinery. Over the last seventeen years, however, complex and essential roles for a cohort of over 350 coactivator proteins have steadily emerged. Coregulator proteins have the uncanny ability to bind across unrelated families of transcription factors and coordinately facilitate the efficient and successful transcriptional activity of multiple target genes"
(http://www.ijbs.com/v08p0470.htm).

Lonard and O'Malley decided to disrupt key signaling pathways and kill cancer cells by overstimulating SRCs. They screened hundreds of thousands of compounds to identify a potent SRC activator, MCB-613, that killed human breast, prostate, lung, and liver cancer cells, while sparing normal cells. When they administered MCB-613 to 13 mice with breast cancer, the drug candidate almost completely eliminated tumor growth without causing toxicity, whereas tumors continued to grow in the control group of 14 mice.

O'Malley concludes, "We are optimistic that these drugs will eventually find their way into the clinic for use in patients."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
MAY 30, 2018
Cell & Molecular Biology
MAY 30, 2018
Diagnosing Deadly Kidney Cancers Sooner
Researchers have found that deadly kidney cancers can be identified by assessing their evolutionary path, which is different for distinct types....
JUN 05, 2018
Cancer
JUN 05, 2018
Early Breast Cancer Patients Do Not Gain Response Advantage with Chemotherapy
Phase III clinical trial research shows evidence that early breast cancer patients with common breast cancer type do not need chemotherapy & hormone therapy combo; hormone therapy is enough...
JUN 25, 2018
Cancer
JUN 25, 2018
B-cell Lymphoma Develops After MPN JAK1/2 Therapy
Patients with myeloproliferative neoplasms treated with JAK1/2 inhibitor therapy are at increased risk of developing aggressive B-cell lymphoma due to pre-existing B-cell clone specifically a...
JUL 10, 2018
Cancer
JUL 10, 2018
Risk Allele Variant SNP at 14q11.2 Linked to ALL
Researchers utilized genome-wide association studies to identify a variant SNP within a gene at 14q11.2 which is linked to ALL....
AUG 07, 2018
Cancer
AUG 07, 2018
Potential Bcl-2 Targeted Therapy for Relapsed Multiple Myeloma Patients
Targeted therapy for Bcl-2 may be helpful in more than the two lymphoma diagnoses that were recently approved by the FDA....
AUG 21, 2018
Immunology
AUG 21, 2018
T cells Trapped by Brain Cancer
Brain tumors prevent T cells from escaping the bone marrow by altering levels of the S1P1 protein....
Loading Comments...